Clinical Trials Browser

Withdrawn × ruxolitinib × Other hematologic neoplasm × Clear all

NCT02973711 2021-02-16

A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04016116 2020-05-27

Dual PD-1 and JAK2 Inhibition in Hematological Malignancies

Phase 2 Withdrawn

Other hematologic neoplasm

Neoplasms, Hematologic Neoplasms